Study of AQUAVAN® Injection (AQUAVAN; Fospropofol Disodium) for Sedation During Colonoscopy

• Number of Patients/Site: Approximately 125 patients, 25 per arm, at up to 25 sites willbe randomized into this study.

• Study Country Location: United States

• Study Population: Male and female patients aged 18 years and older and undergoingelective colonoscopy will be enrolled in the study. Inclusion Criteria:

1. Patient provides signed/dated informed consent and Health Insurance Portability andAccountability Act of 1996 (HIPAA) authorization after receiving a full explanation ofthe extent and nature of the study

2. Patient must be at least 18 years of age at the time of screening

3. If female, patient must be surgically sterile, postmenopausal, or not pregnant orlactating and has been using an acceptable method of birth control for at least 1month prior to dosing, with a negative urine pregnancy test result at screening andpre-dose

4. Patient meets American Society of Anesthesiologists (ASA) Physical ClassificationSystem status of P1 to P4

Exclusion Criteria:

1. Patient has a history of allergic reaction or hypersensitivity to any anestheticagent, narcotic, or benzodiazepine

2. Patient does not meet nils per os (NPO) status per ASA guidelines or institution'sguidelines

3. Patient has a Mallampati classification score of 4; OR a Mallampati classificationscore of 3 AND a thyromental distance <= 4 cm, or for any other reason has a difficultairway, in the opinion of the Investigator

4. Patient has an abnormal, clinically significant 12-lead ECG finding at predosingperiod Day 0

5. Patient has participated in an investigational drug study within 1 month prior tostudy start

6. Patient is unwilling to adhere to pre- and post-procedural instructions

7. Patient for whom the use of fentanyl is contraindicated

8. Patient for whom the use of Midazolam HCl injection (Midazolam) is contraindicated